Ho Y.-S.Chen C.-H.Wang Y.-J.Pestell R.G.Albanese C.Chen R.-J.Chang M.-C.JIIANG-HUEI JENGLin S.-Y.Liang Y.-C.Tseng H.Lee W.-S.Lin J.-K.Chu J.-S.Chen L.-C.Lee C.-H.Tso W.-L.Lai Y.-C.Wu C.-H.2021-07-082021-07-0820050041-008Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-21044454180&doi=10.1016%2fj.taap.2004.09.019&partnerID=40&md5=d14f8a3f06082d71861279d6bd785b62https://scholars.lib.ntu.edu.tw/handle/123456789/570721Cigarette smoke contains several carcinogens known to initiate and promote tumorigenesis as well as metastasis. Nicotine is one of the major components of the cigarette smoke and the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a tobacco-specific carcinogen. Here, we demonstrated that NNK stimulated cell proliferation in normal human bronchial epithelial cells (NHBE) and small airway epithelial cells (SAEC). Cells exposed to NNK resulted in an increase in the level of cyclin D1 protein (as early as 3-6 h). Increased phosphorylation of the Rb Ser795 was detected at 6-15 h after NNK treatment and thereby promoted cells entering into the S phase (at 15-21 h). The increased cyclin D1 protein level was induced through activation of the transcription factor, nuclear factor kB (NFκB), in the NHBE cells. Treatment of the NHBE cells with PD98059, an ERK1/2 (extracellular signal-regulated protein kinase)-specific inhibitor, specifically suppressed the NNK-induced IκBα phosphorylation at position 32 of the serine residue, suggesting that the ERK1/2 kinase was involved in the IκBα phosphorylation induced by NFκB activation. To determine whether the NNK-induced NFκB activation and cyclin D1 induction were also observed in vivo, A/J mice were treated with NNK (9.1 mg) for 20 weeks and the results showed a significant induction of cyclin D1 and NFκB translocation determined by immunoblotting analyses. We further demonstrated that the nicotine acetylcholine receptor (nAchR), which contains the α3-subunit, was the major target mediating NNK-induced cyclin D1 expression in the NHBE cells. In summary, our findings demonstrate for the first time that NNK could stimulate normal human bronchial cell proliferation through activation of the NFκB, which in turn up-regulated the cyclin D1 expression. ? 2004 Elsevier Inc. All rights reserved.Cyclin D1; Lung cancer; NFκB; Nicotine; NNK[SDGs]SDG32 (2 amino 3 methoxyphenyl)chromone; 4 (methylnitrosamino) 1 (3 pyridyl) 1 butanone; carcinogen; cholinergic receptor; cyclin D1; I kappa B alpha; immunoglobulin enhancer binding protein; mitogen activated protein kinase 1; mitogen activated protein kinase 3; mitogen activated protein kinase inhibitor; serine; transcription factor; animal experiment; animal model; article; bronchus mucosa; cell cycle S phase; cell proliferation; cell stimulation; controlled study; enzyme activation; epithelium cell; human; human cell; immunoblotting; mouse; nonhuman; normal human; protein expression; protein localization; protein phosphorylation; upregulation; Bronchi; Carcinogens; Cell Proliferation; Cells, Cultured; Cyclin D1; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; NF-kappa B; Nitrosamines; Phosphorylation; Receptors, Nicotinic; Retinoblastoma Protein; Up-Regulation; Nicotiana tabacumTobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFκB activation and cyclin D1 up-regulationjournal article10.1016/j.taap.2004.09.019158935412-s2.0-21044454180